Status:

COMPLETED

To Evaluate if Dexmedetomidine Infusion Provides Renal Protection in Patients Undergoing Coronary Artery Bypass Graft

Lead Sponsor:

National Institute of Cardiovascular Diseases, Pakistan

Conditions:

Acute Kidney Injury

Eligibility:

All Genders

18-65 years

Phase:

PHASE2

PHASE3

Brief Summary

OBJECTIVE: Aim of this study is to follow and compare the changes in serum creatinine and urine output up to 48 hours of surgery in patients receiving dexmedetomidine infusion in addition to standard ...

Detailed Description

INTRODUCTION: The incidence of cardiac surgery-associated acute kidney injury (CSA-AKI) varies from 5 to 42%.1 This percentage was found to be 7.86% according to study conducted in Pakistan. 2 Severe...

Eligibility Criteria

Inclusion

  • Ages ranged between 18 and 65 years.
  • Patients undergoing isolated coronary artery bypass grafting.
  • Class II and III ASA physical status.

Exclusion

  • Patients with preoperative renal impairment (elevated creatinine and blood urea nitrogen levels) and diuretic use.
  • Preexisting hepatic or pulmonary disease, peripheral vascular disease, previous cardiac surgery, emergency surgery, reopening surgeries, surgeries requiring a deep hypothermic circulatory arrest.
  • Preoperative use of inotropes or vasopressors.
  • Perioperative use of diuretics.
  • Perioperative episode of CPR.
  • Diabetic patients.
  • Preoperative hemoglobin level less than 12 mg/dl.
  • Hematological disorders.
  • Morbidly obese patients.

Key Trial Info

Start Date :

August 1 2021

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 31 2022

Estimated Enrollment :

60 Patients enrolled

Trial Details

Trial ID

NCT05375188

Start Date

August 1 2021

End Date

January 31 2022

Last Update

May 16 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

NICVD Karachi

Karachi, Sindh, Pakistan, 75100